Physician profile
Gregory M Bernstein
NPI 1275553836
$17,571.57
in general payments reported to CMS, 2019-2025
26 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $89.84 · 2021: $401 · 2022: $675 · 2023: $12K · 2024: $3,611 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $2,493 · Travel and Lodging: $1,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,505.00 |
| Food and Beverage | $2,492.85 |
| Travel and Lodging | $1,008.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $13,576.44 | 2021-2025 | Aquabeam Robotic System, Aquabeam System |
| Boston Scientific Corporation | $1,699.00 | 2019-2025 | Ams 700, Ams 700 Cxr Rte Kit, Rezum Generator |
| Edap Technomed INC | $714.00 | 2024 | |
| Endo Pharmaceuticals INC. | $651.26 | 2019-2024 | Xiaflex |
| Coloplast Corp | $194.00 | 2022-2023 | Speedicath, Porges Coloplast |
| Laborie Medical Technologies Corp. | $74.81 | 2022-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Abbvie INC. | $73.23 | 2022-2025 | |
| Olympus America INC. | $70.25 | 2022 | |
| Astellas Pharma US INC | $63.08 | 2019-2023 | Myrbetriq |
| Teleflex LLC | $51.05 | 2021 | |
| Urovant Sciences INC | $48.61 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $45.23 | 2023-2024 | Prolaris |
| Endo USA, INC. | $40.62 | 2024-2025 | Xiaflex |
| Ethicon US, LLC | $28.68 | 2023 | Stratafix, Echelon Flex |
| Sumitomo Pharma America, INC. | $28.67 | 2025 | Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $26.94 | 2022 | |
| Urogen Pharma, INC. | $24.19 | 2024 | |
| Dendreon Pharmaceuticals LLC | $23.85 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $21.69 | 2019 | |
| 180 Medical, INC. | $21.67 | 2019 | |
| Immunitybio, INC. | $20.56 | 2025 | |
| Antares Pharma, INC. | $17.67 | 2021 | |
| Aesculap, INC. | $17.31 | 2019 | |
| Pfizer INC. | $14.63 | 2019 | |
| Metuchen Pharmaceuticals | $12.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.